Form 4: DaVita Inc. Executive Michael Staffieri Reports Stock Transactions

Chief Operating Officer of DaVita Kidney Care, Michael Staffieri, reports acquisition and disposal of DaVita Inc. stock, including shares received from vested performance stock units and shares withheld for tax obligations.

Summary

• Michael Staffieri, Chief Operating Officer of DaVita Kidney Care, filed a Form 4 detailing changes in beneficial ownership of DaVita Inc. stock.
• On March 14, 2024, Staffieri acquired 21,524 shares and 2,167 shares of common stock related to performance stock units vesting.
• On March 15, 2024, Staffieri acquired 13,172 restricted stock units and disposed of 12,008 shares to cover tax obligations.
• Following these transactions, Staffieri directly owns 92,978 shares of common stock and indirectly owns 158,506 shares through the 2012 Staffieri Family Trust.
• The restricted stock units are scheduled to vest 50% each on March 15, 2027, and March 15, 2028, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of performance stock units suggests the company met certain performance goals. The sale of shares for tax purposes is a normal occurrence.

Positives

• The vesting of performance stock units indicates that performance criteria were met, which could be seen as a positive signal.

Negatives

• The disposal of 12,008 shares to cover tax obligations could be interpreted as a slight negative, although it's a common practice.

Risks

• Future stock performance could impact the value of Staffieri's holdings.
• Changes in company strategy or performance could affect the vesting of future restricted stock units.

Future Outlook

The document indicates future vesting dates for restricted stock units in 2027 and 2028, contingent on continued service.

Industry Context

Executive stock transactions are common and closely monitored in the healthcare industry, providing insights into management's confidence and alignment with shareholder interests. These transactions are typical for executives receiving stock-based compensation.

Comparison to Industry Standards

• Stock-based compensation is a common practice among publicly traded companies, including DaVita's competitors such as Fresenius Medical Care and Baxter International.
• Executive stock ownership is generally viewed positively, aligning management's interests with those of shareholders.
• The vesting schedules for restricted stock units are fairly standard, typically ranging from 3 to 5 years.

Stakeholder Impact

• Shareholders may view the vesting of performance stock units as a positive sign of company performance.
• Employees may be motivated by the potential for future stock-based compensation.

Next Steps

• The restricted stock units will vest in 2027 and 2028, subject to continued service.
• Future Form 4 filings will likely be made to report any further changes in beneficial ownership.

Key Dates